MSB 3.21% $1.13 mesoblast limited

t2d - very interesting...but, page-11

  1. 332 Posts.
    lightbulb Created with Sketch. 17
    gpeters2 - The following appears promising to me. It is cut & pasted from the MSB results (from your post):
    ---
    • In the less well-controlled subjects, as defined by a baseline HbA1c >8.0%, a 0.6% decrease in HbA1c was seen at 8 weeks in the high dose cohort compared with placebo.
    • In those with baseline HbA1c <8%, a target of HbA1c <7% at week 12 was achieved in 63% (5/8) of high-dose treated subjects compared with 0/7 placebo controls (p<0.05).
    ---
    I'm not familiar with other potential T2D interventions that may be better, but if there was nothing else I'd be quick to participate in a longer Phase 3 trial based on the Phase 2 results. Not that I suffer T2D, but if I did...

    Having said that, I don't think the market is putting any value on MSB's T2D potential.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.